ixazomib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1 (1)
Phase 2 (1)

Interventional (2)

Institute of Hematology & Blood Diseases Hospital (1)
University of Pennsylvania (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadmeasurable disease

I am/have/hadmultiple myeloma

I am/have/hadabsolute neutrophil count

I am/have/hadamyloidosis

I am/have/hadwaldenstrom's macroglobulinemia

I am/have/hadremission

I am/have/hadlymphoma

I am/have/hadfever

I am/have/hadindolent lymphoma

I am/have/hadcytopenia

I am/have/hadneutrophil count

I am/have/hadcold agglutinin

I am/have/hadcryoglobulinemia

I am/have/hadneuropathy

I am/have/hadtreatment regimen

I am/have/hadnight sweats

added new label for I am/have/had

more

I am looking for

I am looking forixazomib

I am looking fordexamethasone

I am looking forcyclophosphamide

I am looking forfludarabine

I am looking forchlorambucil

I am looking forzanubrutinib

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Oncology
Recruiting

Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will be given up to 24 months and stopped for observation.

fever

cytopenia

cryoglobulinemia

zanubrutinib

absolute neutrophil count

0 views
19 Feb, 2024

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

multiple myeloma

measurable disease

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.